ACE2 as a Potential Target for Management of Novel Coronavirus (nCoV- 2019)

Title:ACE2 as a Potential Target for Management of Novel Coronavirus (nCoV- 2019)

Volume: 18 Issue: 6

Author(s): Elham Foroozanfar, Mohamad Forouzanfar, Tahereh Farkhondeh, Saeed Samarghandian and Fatemeh Forouzanfar*

Affiliation:

• Department of Neuroscience, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad,,Iran

Keywords: COVID-19, renin-angiotensin system, ACE2, angiotensin, SARS-like coronavirus, acute respiratory syndrome.

Abstract: A novel coronavirus termed nCoV-2019 that caused an epidemic of acute respiratory syndrome in humans was first detected in Wuhan, China, in December 2019. nCoV-2019 resulted in thousands of cases of lethal disease all around the world. Unfortunately, there is no specific treatment yet, so a better understanding of the pathobiology of the disease can be helpful. The renin-angiotensin system and its products have several important physiological actions. On the other hand, this system is involved in the pathogenesis of various diseases. In this context, this review article will briefly discuss insights for understanding the role of the angiotensin-converting enzyme 2 (ACE2) receptor as a potentially attractive target for the nCoV-2019-induced acute respiratory syndrome.

Cite this article as:

Foroozanfar Elham , Forouzanfar Mohamad , Farkhondeh Tahereh , Samarghandian Saeed and Forouzanfar Fatemeh *, ACE2 as a Potential Target for Management of Novel Coronavirus (nCoV- 2019), Current Drug Discovery Technologies 2021; 18 (6) : e130921189567 . https://dx.doi.org/10.2174/1570163817999201228215911